| An oral FDC of decitabine and cedazuridine is being developed by Astex Pharmaceuticals for the treatment of cancers, such as MDS, CMML and AML |
| Received its first approval on 7 July 2020 in the USA and Canada |
| Approved for the treatment of adults with MDS and CMML |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.